Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 50.70
-0.30 (-0.59%)
Jan 13, 2026, 9:45 AM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 13.51 billion as of January 12, 2026. Its market cap has increased by 30.45% in one year.
Market Cap
13.51B
Enterprise Value
13.66B
Revenue
224.83M
Ranking
n/a
PE Ratio
n/a
Stock Price
50.70
Market Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 13.51B, a decrease of -19.47%. That is a compound annual growth rate of -2.06%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 9, 2026 | 13.96B | -4.18% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 228.62B |
| PharmaEssentia | 189.36B |
| Lotus Pharmaceutical | 76.92B |
| Bora Pharmaceuticals Co., LTD. | 64.12B |
| Heron Neutron Medical | 59.70B |
| Oneness Biotech | 33.15B |
| Lumosa Therapeutics | 31.67B |
| Center Laboratories | 30.53B |